Recent Updates — ENSC

On August 5, 2026, Ensysce Biosciences completed its acquisition of Cy Biopharma pursuant to a merger agreement. As consideration, Ensysce issued Series C Preferred Stock convertible into common stock and raised approximately $21.5 million in gross proceeds through a concurrent private placement of additional Series C shares. The transaction expands Ensysce's pipeline to include Cy Biopharma’s neuroplastogenic therapies for severe chronic pain, specifically psilocybin-based candidates CY200 and CY201 for Complex Regional Pain Syndrome (CRPS). Ensysce is a clinical-stage pharmaceutical company developing abuse-resistant opioid prodrugs and novel pain treatments.

Ensysce Biosciences completed the acquisition of Cy Biopharma on August 5, 2026, issuing 282,122 shares of Series C Preferred Stock to Cy's equityholders. Concurrently, Ensysce raised approximately $43 million in a private placement by selling 120,260 shares of Series C Preferred Stock at an aggregate price of roughly $321.79 per share for the initial tranche and $402.24 per share for the milestone tranche. The company also terminated agreements with 3i, LP, converting outstanding Series B Preferred Stock into common stock and paying a $250,000 settlement. Lynn Kirkpatrick resigned as President while remaining CEO, and James Morrison was appointed President and Director. Ensysce Biosciences is a clinical-stage biotechnology company developing novel analgesic therapies.

On July 10, 2026, Jeffrey Millard resigned from his position as Chief Operating Officer of Ensysce Biosciences, Inc., effective immediately. The company operates in the biotechnology industry, focusing on the development of non-opioid pain therapies.